{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:58:07Z","timestamp":1785358687583,"version":"3.55.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-204039"],"award-info":[{"award-number":["PJT-204039"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropeptides"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.npep.2026.102633","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T15:25:23Z","timestamp":1780154723000},"page":"102633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Re-thinking neuropeptide therapeutics: What Neuropeptide Y and Galanin teach us about stress, resilience, and drug design"],"prefix":"10.1016","volume":"118","author":[{"given":"Grinal","family":"Corriea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Sibille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.npep.2026.102633_bb0005","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1016\/j.peptides.2006.07.020","article-title":"Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze","volume":"27","author":"Bacchi","year":"2006","journal-title":"Peptides"},{"issue":"4","key":"10.1016\/j.npep.2026.102633_bb0010","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.npep.2004.04.006","article-title":"Neuropeptide Y and epilepsy: recent progress, prospects and controversies","volume":"38","author":"Baraban","year":"2004","journal-title":"Neuropeptides"},{"issue":"52","key":"10.1016\/j.npep.2026.102633_bb0015","doi-asserted-by":"crossref","first-page":"E8472","DOI":"10.1073\/pnas.1617824113","article-title":"Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide","volume":"113","author":"Barde","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.npep.2026.102633_bb0020","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJMoa030204","article-title":"Inhibition of food intake in obese subjects by peptide YY3-36","volume":"349","author":"Batterham","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.npep.2026.102633_bb0025","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1053\/j.gastro.2016.12.050","article-title":"Blaming the brain for obesity: integration of hedonic and homeostatic mechanisms","volume":"152","author":"Berthoud","year":"2017","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.npep.2026.102633_bb0030","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/bph.12037","article-title":"Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity","volume":"170","author":"Boughton","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"19","key":"10.1016\/j.npep.2026.102633_bb0035","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1073\/pnas.1318066111","article-title":"GAL3 receptor KO mice exhibit an anxiety-like phenotype","volume":"111","author":"Brunner","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.npep.2026.102633_bb0040","article-title":"NPY and gene therapy for epilepsy: how, when,\u2026 and Y","volume":"13","author":"Cattaneo","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"4","key":"10.1016\/j.npep.2026.102633_bb0045","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/cne.902730409","article-title":"Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia","volume":"273","author":"Chan-Palay","year":"1988","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.npep.2026.102633_bb0050","article-title":"Meta-analysis on the association of neuropeptide Y rs16139 variant with the risk of alcoholism","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Psychol."},{"issue":"1","key":"10.1016\/j.npep.2026.102633_bb0055","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1038\/s41598-023-36178-1","article-title":"A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss","volume":"13","author":"Chichura","year":"2023","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.npep.2026.102633_bb0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1535-7597.2003.03208.x","article-title":"Neuropeptide Y and epilepsy","volume":"3","author":"Colmers","year":"2003","journal-title":"Epilepsy Curr."},{"issue":"4","key":"10.1016\/j.npep.2026.102633_bb0065","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3233\/JAD-2009-1196","article-title":"Galanin fiber hyperinnervation preserves neuroprotective gene expression in cholinergic basal forebrain neurons in Alzheimer\u2019s disease","volume":"18","author":"Counts","year":"2009","journal-title":"J. Alzheimers Dis."},{"issue":"6","key":"10.1016\/j.npep.2026.102633_bb0070","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/sj.bjp.0703162","article-title":"BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist","volume":"129","author":"Dumont","year":"2000","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.npep.2026.102633_bb0075","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cmet.2006.08.002","article-title":"Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults","volume":"4","author":"Erondu","year":"2006","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.npep.2026.102633_bb0080","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/oby.2007.620","article-title":"Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss","volume":"15","author":"Erondu","year":"2007","journal-title":"Obesity"},{"issue":"8","key":"10.1016\/j.npep.2026.102633_bb0085","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/oby.2007.242","article-title":"NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine","volume":"15","author":"Erondu","year":"2007","journal-title":"Obesity"},{"issue":"15","key":"10.1016\/j.npep.2026.102633_bb0090","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1523\/JNEUROSCI.21-15-05804.2001","article-title":"Plasticity of Y1 and Y2 receptors and neuropeptide Y fibers in patients with temporal lobe epilepsy","volume":"21","author":"Furtinger","year":"2001","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.npep.2026.102633_bb0095","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0195-668X(03)00209-4","article-title":"The effect of a neuropeptide Y Y1 receptor antagonist in patients with angina pectoris","volume":"24","author":"Gullestad","year":"2003","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.npep.2026.102633_bb0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/14017431.2011.624195","article-title":"Differential effects of metoprolol and atenolol to neuropeptide Y blockade in coronary artery disease","volume":"46","author":"Gullestad","year":"2012","journal-title":"Scand. Cardiovasc. J."},{"issue":"1","key":"10.1016\/j.npep.2026.102633_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-0115(01)00234-8","article-title":"Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor","volume":"99","author":"Haskell-Luevano","year":"2001","journal-title":"Regul. Pept."},{"issue":"4","key":"10.1016\/j.npep.2026.102633_bb0110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.npep.2004.05.002","article-title":"The NPY system in stress, anxiety and depression","volume":"38","author":"Heilig","year":"2004","journal-title":"Neuropeptides"},{"issue":"5","key":"10.1016\/j.npep.2026.102633_bb0115","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1055\/s-2007-978748","article-title":"Galanin and NPY, two peptides with multiple putative roles in the nervous system","volume":"31","author":"H\u00f6kfelt","year":"1999","journal-title":"Horm. Metab. Res. Horm. Stoffwechselforschung Horm. Metab."},{"issue":"34","key":"10.1016\/j.npep.2026.102633_bb0120","doi-asserted-by":"crossref","first-page":"14943","DOI":"10.1073\/pnas.1010365107","article-title":"Neuropeptide receptor positive allosteric modulation in epilepsy: galanin modulation revealed","volume":"107","author":"Hoyer","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.npep.2026.102633_bb0125","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/cbdv.201200288","article-title":"Neuropeptides and neuropeptide receptors: drug targets, and peptide and non-peptide ligands: a tribute to prof. Dieter Seebach","volume":"9","author":"Hoyer","year":"2012","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.npep.2026.102633_bb0130","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT01413932. 2026."},{"key":"10.1016\/j.npep.2026.102633_bb0135","unstructured":"https:\/\/www.shionogi.com\/content\/dam\/shionogi\/global\/news\/pdf\/2009\/e_090217-2.pdf. 2026."},{"issue":"21","key":"10.1016\/j.npep.2026.102633_bb0140","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121465119","article-title":"Structural insights into galanin receptor signaling","volume":"119","author":"Jiang","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"22","key":"10.1016\/j.npep.2026.102633_bb0145","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1007\/s00018-019-03432-7","article-title":"Biased agonists at the human Y1 receptor lead to prolonged membrane residency and extended receptor G protein interaction","volume":"77","author":"Kaiser","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.npep.2026.102633_bb0150","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.str.2022.11.010","article-title":"Structural basis for Y2 receptor-mediated neuropeptide Y and peptide YY signaling","volume":"31","author":"Kang","year":"2023","journal-title":"Structure"},{"issue":"3","key":"10.1016\/j.npep.2026.102633_bb0155","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00726-006-0336-8","article-title":"Galanin as a modulator of anxiety and depression and a therapeutic target for affective disease","volume":"31","author":"Karlsson","year":"2006","journal-title":"Amino Acids"},{"issue":"1","key":"10.1016\/j.npep.2026.102633_bb0160","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0021-9150(01)00468-3","article-title":"Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men","volume":"159","author":"Karvonen","year":"2001","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.npep.2026.102633_bb0165","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd3954","article-title":"Signalling bias in new drug discovery: detection, quantification and therapeutic impact","volume":"12","author":"Kenakin","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1\u20132","key":"10.1016\/j.npep.2026.102633_bb0170","first-page":"76","article-title":"The \u2018Trier Social Stress Test\u2019--a tool for investigating psychobiological stress responses in a laboratory setting","volume":"28","author":"Kirschbaum","year":"1993","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.npep.2026.102633_bb0175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.npep.2015.12.003","article-title":"In vitro toxicity of the galanin receptor 3 antagonist SNAP 37889","volume":"56","author":"Koller","year":"2016","journal-title":"Neuropeptides"},{"issue":"1","key":"10.1016\/j.npep.2026.102633_bb0180","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.euroneuro.2006.03.003","article-title":"Galanin enhances and a galanin antagonist attenuates depression-like behaviour in the rat","volume":"17","author":"Kuteeva","year":"2007","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.npep.2026.102633_bb0185","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1124\/pr.112.006536","article-title":"Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity","volume":"67","author":"Lang","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.npep.2026.102633_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2022.102231","article-title":"Crystal structures of human neuropeptide Y (NPY) and peptide YY (PYY)","volume":"92","author":"Langley","year":"2022","journal-title":"Neuropeptides"},{"issue":"3","key":"10.1016\/j.npep.2026.102633_bb0195","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0167-0115(96)00110-3","article-title":"Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide","volume":"65","author":"Larhammar","year":"1996","journal-title":"Regul. Pept."},{"issue":"7","key":"10.1016\/j.npep.2026.102633_bb0200","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1046\/j.1460-9568.2003.02926.x","article-title":"Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development","volume":"18","author":"Lin","year":"2003","journal-title":"Eur. J. Neurosci."},{"issue":"34","key":"10.1016\/j.npep.2026.102633_bb0205","doi-asserted-by":"crossref","first-page":"15229","DOI":"10.1073\/pnas.1008986107","article-title":"GalR2-positive allosteric modulator exhibits anticonvulsant effects in animal models","volume":"107","author":"Lu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5748","key":"10.1016\/j.npep.2026.102633_bb0210","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1126\/science.1115524","article-title":"NPY\/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates","volume":"310","author":"Luquet","year":"2005","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.npep.2026.102633_bb0215","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/nn.2139","article-title":"The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress","volume":"11","author":"Lutter","year":"2008","journal-title":"Nat. Neurosci."},{"issue":"16","key":"10.1016\/j.npep.2026.102633_bb0220","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s40265-020-01414-9","article-title":"Oliceridine: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.npep.2026.102633_bb0225","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/ijnp\/pyaa054","article-title":"A randomized controlled trial of intranasal neuropeptide Y in patients with major depressive disorder","volume":"23","author":"Math\u00e9","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5 Pt 2","key":"10.1016\/j.npep.2026.102633_bb0230","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1523\/JNEUROSCI.15-05-03990.1995","article-title":"Reactive synaptogenesis and neuron densities for neuropeptide Y, somatostatin, and glutamate decarboxylase immunoreactivity in the epileptogenic human fascia dentata","volume":"15","author":"Mathern","year":"1995","journal-title":"J. Neurosci."},{"issue":"16","key":"10.1016\/j.npep.2026.102633_bb0235","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1523\/JNEUROSCI.20-16-06276.2000","article-title":"Modulation of hippocampal excitability and seizures by galanin","volume":"20","author":"Mazarati","year":"2000","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.npep.2026.102633_bb0240","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0167-0115(93)90435-B","article-title":"Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV","volume":"49","author":"Mentlein","year":"1993","journal-title":"Regul. Pept."},{"issue":"2","key":"10.1016\/j.npep.2026.102633_bb0245","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/epi.13647","article-title":"Preclinical evaluation of intravenous NAX 810-2, a novel GalR2-preferring analog, for anticonvulsant efficacy and pharmacokinetics","volume":"58","author":"Metcalf","year":"2017","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.npep.2026.102633_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061297","article-title":"Galanin and neuropeptide Y interaction enhances proliferation of granule precursor cells and expression of neuroprotective factors in the rat hippocampus with consequent augmented spatial memory","volume":"10","author":"Mirchandani-Duque","year":"2022","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.npep.2026.102633_bb0255","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0006-3223(99)00239-5","article-title":"Plasma neuropeptide-Y concentrations in humans exposed to military survival training","volume":"47","author":"Morgan","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.npep.2026.102633_bb0260","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.eplepsyres.2009.02.020","article-title":"Different phases of afterdischarge during rapid kindling procedure in mice","volume":"85","author":"Musto","year":"2009","journal-title":"Epilepsy Res."},{"issue":"5335","key":"10.1016\/j.npep.2026.102633_bb0265","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1126\/science.278.5335.135","article-title":"Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein","volume":"278","author":"Ollmann","year":"1997","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.npep.2026.102633_bb0270","article-title":"Structural basis of neuropeptide Y signaling through Y1 receptor","volume":"13","author":"Park","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.npep.2026.102633_bb0275","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fendo.2013.00005","article-title":"Neuropeptide Y receptors: how to get subtype selectivity","volume":"4","author":"Pedragosa-Badia","year":"2013","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.npep.2026.102633_bb0280","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0013-4694(72)90176-9","article-title":"Modification of seizure activity by electrical stimulation. I. After-discharge threshold","volume":"32","author":"Racine","year":"1972","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"10.1016\/j.npep.2026.102633_bb0285","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.npep.2015.09.008","article-title":"Neuropeptide Y: a stressful review","volume":"55","author":"Reichmann","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.npep.2026.102633_bb0290","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s42003-018-0134-3","article-title":"Conformational signatures in \u03b2-arrestin2 reveal natural biased agonism at a G-protein-coupled receptor","volume":"1","author":"Reyes-Alcaraz","year":"2018","journal-title":"Commun. Biol."},{"issue":"12","key":"10.1016\/j.npep.2026.102633_bb0295","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1523\/JNEUROSCI.4056-03.2004","article-title":"Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus","volume":"24","author":"Richichi","year":"2004","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.npep.2026.102633_bb0300","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-2125.2009.03550.x","article-title":"New central targets for the treatment of obesity","volume":"68","author":"Sargent","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.npep.2026.102633_bb0305","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ijnp\/pyx109","article-title":"A randomized dose-ranging study of neuropeptide Y in patients with posttraumatic stress disorder","volume":"21","author":"Sayed","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"17","key":"10.1016\/j.npep.2026.102633_bb0310","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.1021\/acs.jmedchem.7b00976","article-title":"Identification and characterization of the first selective Y4 receptor positive allosteric modulator","volume":"60","author":"Schubert","year":"2017","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.npep.2026.102633_bb0315","doi-asserted-by":"crossref","first-page":"8745","DOI":"10.1021\/acs.jmedchem.3c00383","article-title":"Structure-activity relationship study of the high-affinity neuropeptide Y4 receptor positive allosteric modulator VU0506013","volume":"66","author":"Sch\u00fc\u00df","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.npep.2026.102633_bb0320","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-025-06019-7","article-title":"The pathway-independent positive allosteric modulator C1 allows for the identification of active Y4 receptor relevant positions","volume":"83","author":"Sch\u00fc\u00df","year":"2026","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.npep.2026.102633_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1137604","article-title":"Allosteric modulation of G protein-coupled receptor signaling","volume":"14","author":"Shen","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1\u20132","key":"10.1016\/j.npep.2026.102633_bb0330","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0009-8981(02)00301-7","article-title":"Neuropeptide Y and its receptors as potential therapeutic drug targets","volume":"326","author":"Silva","year":"2002","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"issue":"1","key":"10.1016\/j.npep.2026.102633_bb0335","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1124\/jpet.116.236372","article-title":"An allosteric Potentiator of the dopamine D1 receptor increases locomotor activity in human D1 Knock-in mice without causing stereotypy or Tachyphylaxis","volume":"360","author":"Svensson","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"48","key":"10.1016\/j.npep.2026.102633_bb0340","doi-asserted-by":"crossref","first-page":"17489","DOI":"10.1073\/pnas.0508970102","article-title":"Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299","volume":"102","author":"Swanson","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.npep.2026.102633_bb0345","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2147\/JPR.S278279","article-title":"Oliceridine: a novel drug for the Management of Moderate to severe acute pain - a review of current evidence","volume":"14","author":"Tan","year":"2021","journal-title":"J. Pain Res."},{"issue":"18","key":"10.1016\/j.npep.2026.102633_bb0350","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm1232","article-title":"Receptor-specific recognition of NPY peptides revealed by structures of NPY receptors","volume":"8","author":"Tang","year":"2022","journal-title":"Sci. Adv."},{"issue":"18","key":"10.1016\/j.npep.2026.102633_bb0355","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1523\/JNEUROSCI.0430-10.2010","article-title":"The central and basolateral amygdala are critical sites of neuropeptide Y\/Y2 receptor-mediated regulation of anxiety and depression","volume":"30","author":"Tasan","year":"2010","journal-title":"J. Neurosci."},{"issue":"18","key":"10.1016\/j.npep.2026.102633_bb0360","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1073\/pnas.79.18.5485","article-title":"Neuropeptide Y: complete amino acid sequence of the brain peptide","volume":"79","author":"Tatemoto","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5858","key":"10.1016\/j.npep.2026.102633_bb0365","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/296659a0","article-title":"Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide","volume":"296","author":"Tatemoto","year":"1982","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.npep.2026.102633_bb0370","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/0014-5793(83)80033-7","article-title":"Galanin - a novel biologically active peptide from porcine intestine","volume":"164","author":"Tatemoto","year":"1983","journal-title":"FEBS Lett."},{"key":"10.1016\/j.npep.2026.102633_bb0375","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1196\/annals.1410.083","article-title":"Central neuropeptide Y in anxiety- and stress-related behavior and in ethanol intake","volume":"1148","author":"Thorsell","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2\u20133","key":"10.1016\/j.npep.2026.102633_bb0380","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1054\/npep.2002.0897","article-title":"Diverse functions of neuropeptide Y revealed using genetically modified animals","volume":"36","author":"Thorsell","year":"2002","journal-title":"Neuropeptides"},{"key":"10.1016\/j.npep.2026.102633_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2018.00220","article-title":"The orexin\/receptor system: molecular mechanism and therapeutic potential for neurological diseases","volume":"11","author":"Wang","year":"2018","journal-title":"Front. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.npep.2026.102633_bb0390","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.nurt.2009.01.001","article-title":"Developing novel antiepileptic drugs: characterization of NAX 5055, a systemically-active galanin analog, in epilepsy models","volume":"6","author":"White","year":"2009","journal-title":"Neurotherapeutics"},{"issue":"11","key":"10.1016\/j.npep.2026.102633_bb0395","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly Semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.npep.2026.102633_bb0400","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.nbd.2005.05.010","article-title":"Differential suppression of seizures via Y2 and Y5 neuropeptide Y receptors","volume":"20","author":"Woldbye","year":"2005","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.npep.2026.102633_bb0405","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/(SICI)1096-9861(19980309)392:2<227::AID-CNE6>3.0.CO;2-4","article-title":"Galanin\/GMAP- and NPY-like immunoreactivities in locus coeruleus and noradrenergic nerve terminals in the hippocampal formation and cortex with notes on the galanin-R1 and -R2 receptors","volume":"392","author":"Xu","year":"1998","journal-title":"J. Comp. Neurol."},{"issue":"7190","key":"10.1016\/j.npep.2026.102633_bb0410","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/nature06858","article-title":"Genetic variation in human NPY expression affects stress response and emotion","volume":"452","author":"Zhou","year":"2008","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.npep.2026.102633_bb0415","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ana.22548","article-title":"High-frequency oscillations as a new biomarker in epilepsy","volume":"71","author":"Zijlmans","year":"2012","journal-title":"Ann. Neurol."}],"container-title":["Neuropeptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417926000491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417926000491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:58:53Z","timestamp":1785355133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143417926000491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":83,"alternative-id":["S0143417926000491"],"URL":"https:\/\/doi.org\/10.1016\/j.npep.2026.102633","relation":{},"ISSN":["0143-4179"],"issn-type":[{"value":"0143-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-thinking neuropeptide therapeutics: What Neuropeptide Y and Galanin teach us about stress, resilience, and drug design","name":"articletitle","label":"Article Title"},{"value":"Neuropeptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.npep.2026.102633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102633"}}